

Rutgers Catalyst: Healthy Aging Symposium October 18, 2018

Micronutrient Supplementation and the Aging Brain *Can Supplements Prevent Age-Related Cognitive Decline?*

Joshua W. Miller, PhD Professor and Chair Dept. of Nutritional Sciences School of Environmental and Biological Sciences Rutgers, The State University of New Jersey

WAYS TO CUT YOUR ALZHEIMER'S **DISEASE RISK**

Research suggests that certain diet and exercise habits may lower Alzheimer's disease risk by more than half.

Steps to Prevent Alzheimer's

Dairy products, meats, and certain oils (coconut. and palm oils - listed on labels as "partially hydrogenated oils") contain saturated fat. Many snacks, pastries, and fried foods are filled with



Eat a healthy diet

Vegetables, legumes (beans, peas, and lentils), fruits. and whole grains should be staples in your diet.



Go nuts for nuts. One ounce of nuts or seeds - a small handful is a great source of vitamin E

Make vitamin B12 a priority.

Eat fortified foods or take a supplement to get at least the recommended daily allowance (2.4 mcg per day for adults).

Choose your multivitamin wisely. Avoid multivitamins with iron and copper, and take

iron supplements only when directed by your doctor

Cook with caution

Avoid aluminum cookware, which has been linked to Alzheimer's-related dementia, instead choose stainless steel or cast iron pots and pans.

Keep moving. cycling.



Source: Dietary Guidelines for Alzheimer's Prevention 2013, Physicians Committee for Responsible Medicine







PLAN B POSITIVE ACTION ON ALZHEIMER'S

HOMOCYSTEINE AND B VITAMINS





VITAMIN D & DEMENTIA

Press Release – July 16, 2014



Taking B vitamins won't prevent Alzheimer's disease

HEALTH (/NEWS-LISTING?CATEGORY=249)

RESEARCH (/NEWS-LISTING?CATEGORY=228)

Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate.

Clarke et al, Am J Clin Nutr, 2014

Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals^{1–5}

Robert Clarke, Derrick Bennett, Sarah Parish, Sarah Lewington, Murray Skeaff, Simone JPM Eussen, Catharina Lewerin, David J Stott, Jane Armitage, Graeme J Hankey, Eva Lonn, David Spence, Pilar Galan, Lisette C de Groot, Jim Halsey, Alan D Dangour, Rory Collins, and Francine Grodstein on behalf of the B-Vitamin Treatment Trialists' Collaboration

Do Supplements Prevent Cognitive Decline?

Answer...

Probably, but...

B Vitamins, Homocysteine, and Vascular Disease

Effect of B Vitamin Supplements on Brain Atrophy in Older Adults with MCI

Smith et al, PLoS One, 2010

Effect of B Vitamin Supplements on Total Brain Atrophy

Placebo

B Vitamins

B vitamin supplements slow brain atrophy in older adults with mild cognitive impairment and high homocysteine.

∆Hcy: 22 to 30 µmol/L
Atrophy Rate: 2.5%/yr

 Δ Hcy: 24 to 12 µmol/L Atrophy Rate: 0.46%/yr

Smith et al, PLoS One, 2010

Effect of B Vitamin Supplements on Delayed Recall (Short-Term Memory)

B vitamin supplements slow cognitive decline in older adults with mild cognitive impairment and high homocysteine.

De Jager et al, Int J Geriatr Psychiatry, 2011

Press Release – July 16, 2014

Taking B vitamins won't prevent Alzheimer's disease

HEALTH (/NEWS-LISTING?CATEGORY=249)

RESEARCH (/NEWS-LISTING?CATEGORY=228)

Taking B vitamins doesn't slow mental decline as we age, nor is it likely to prevent Alzheimer's disease, conclude Oxford University researchers who have assembled all the best clinical trial data involving 22,000 people to offer a final answer on this debate.

Clarke et al, Am J Clin Nutr, 2014

Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals^{1–5}

Robert Clarke, Derrick Bennett, Sarah Parish, Sarah Lewington, Murray Skeaff, Simone JPM Eussen, Catharina Lewerin, David J Stott, Jane Armitage, Graeme J Hankey, Eva Lonn, David Spence, Pilar Galan, Lisette C de Groot, Jim Halsey, Alan D Dangour, Rory Collins, and Francine Grodstein on behalf of the B-Vitamin Treatment Trialists' Collaboration

Effects of B Vitamins and Homocysteine Lowering on Global Cognitive Function Meta-Analysis of RCTs

Clarke et al, Am J Clin Nutr, 2014

Effects of B Vitamins and Homocysteine Lowering on Domains of Cognitive Function Meta-Analysis of RCTs

©2014 by American Society for Nutrition

Clarke et al, Am J Clin Nutr, 2014

Trajectories of Cognitive Change

Charles DeCarli (unpublished)

Nutrition Reviews 73:723-35, 2015

Special Article

Assessing the association between homocysteine and cognition: reflections on Bradford Hill, meta-analyses, and causality

Andrew McCaddon and Joshua W. Miller

Hyperhomocysteinemia is a recognized risk factor for cognitive decline and incident dementia in older adults. Two recent reports addressed the cumulative epidemiological evidence for this association but expressed conflicting opinions. Here, the evidence is reviewed in relation to Sir Austin Bradford Hill's criteria for assessing "causality," and the latest meta-analysis of the effects of homocysteine-lowering on cognitive function is critically examined. The meta-analysis included 11 trials, collectively assessing 22 000 individuals, that examined the effects of B vitamin supplements (folic acid, vitamin B₁₂, vitamin B₆) on global or domain-specific cognitive decline. It concluded that homocysteine-lowering with B vitamin supplements has no significant effect on cognitive function. However, careful examination of the trials in the meta-analysis indicates that no conclusion can be made regarding the effects of homocysteine-lowering on cognitive decline, since the trials typically did not include individuals who were experiencing such decline. Further definitive trials in older adults experiencing cognitive decline are still urgently needed.

Change in Cognition in Healthy Older Adults You can't prevent something that isn't happening...

Table 2 Changes in cognitive domain scores of elderly people (only participants with baseline and 2-year data)					
	Unadjusted mean (SD)				
	Baseline	2 y	Change (95% CI)	Model 1, p value	Model 2, p value
Episodic memory (n = 2,467)*					
Placebo	0.04 (0.69)	0.13 (0.75)	0.08 (0.05 to 0.12)	0.27	0.42
B vitamins	0.05 (0.69)	0.16 (0.75)	0.11 (0.07 to 0.14)		
Attention and working memory (n = 759)					
Placebo	0.02 (0.86)	-0.04 (0.88)	-0.06 (-0.12 to 0.01)	0.38	0.37
B vitamins	-0.01 (0.84)	-0.10 (0.82)	-0.09 (-0.16 to -0.02)		
Information processing speed (n = 731)					
Placebo	0.08 (0.75)	0.06 (0.79)	-0.02 (-0.06 to 0.01)	0.65	0.51
B vitamins	0.04 (0.75)	0.01 (0.77)	-0.03 (-0.07 to 0.00)		
Executive functioning (n = 720)					
Placebo	0.04 (0.54)	0.10 (0.68)	0.06 (-0.00 to 0.12)	0.20	0.26
B vitamins	-0.01 (0.52)	0.13 (0.66)	0.13 (0.07 to 0.19)		

Abbreviation: Cl = confidence interval.

Differences between the 2 groups over time were measured using analyses of covariance. Model 1: adjusted for baseline domain scores. Model 2: adjusted for baseline domain scores, age, sex.

^a Model 2 additionally adjusted for study center.

Van der Zwaluw et al, Neurology, 2014

Key Considerations

What is the cognitive status of the subjects?

- Cognitively normal?
- Mild cognitive impairment?
- Dementia?

What are the cognitive outcomes?

- Improve cognitive function?
- Slow or prevent cognitive decline?

What cognitive function tests are used?

- MMSE (global)?
- Subdomains?

• What is the B vitamin/homocysteine status of the subjects?

Is homocysteine elevated?

How long is the intervention?

- Months?
- Years?

Challenge and Opportunity

Challenge

 Applying what we've learned from population-based studies to inform personalized medicine and personalized nutrition.

Opportunity

• To design and implement smarter intervention trials with nutritional supplements to determine if age-related cognitive decline can be slowed or prevented.